China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Gold Prices Slip as Strong Dollar and Rising Oil Weigh on Market Sentiment 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
Oil Prices Rise Amid Strait of Hormuz Tensions and U.S.-Iran Ceasefire Uncertainty 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone 
Trump to Visit China for Key U.S.-China Summit With Xi Jinping 
Wall Street Futures Edge Higher as Iran Tensions and AI Optimism Shape Markets 
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case 
Asian Currencies Slip as US Dollar Gains on Rising Iran Tensions and Awaited Jobs Data 
Armani Group Eyes Strategic Stake Sale to Luxury Giants 
Dollar Struggles to Rally Despite Strong US Data as Fed Hike Expectations Remain Limited 
Hyundai Pharmaceutical revealed on Tuesday, July 6, that it has submitted an application so it can start selling its abortion pill in South Korea. The company filed for authorization to market at the Ministry of Food and Drug Safety.
Hyundai Pharm is intending to start selling its Mifegymiso that is composed of four tablets of misoprostol and one tablet of mifepristone. Mifepristone is being sold in Korea under the brand name Mifegyne.
First legal abortion pill in S. Korea
According to The Korea Herald, if the ministry will give a go signal for the sale of Mifegymiso, it would effectively become the very first abortion pill that will be legally marketed in the country. In 2019, the Constitutional Court reversed the ban on abortion in the first 14 weeks of pregnancy, so this paved the way for the pills to be produced.
Hyundai Pharm will be distributing Mifegymiso to the market as a prescription drug. This means that only patients with proper medical advice from health professionals will be able to obtain the drug. Without the supervision of a certified health advisor, an individual will not be allowed to purchase the abortion pill.
The U.S. Food and Drug Administration stated that abortion pills are safe to use in the first nine or 10 weeks of pregnancy. While it seems that more and more groups are supporting and even promoting abortion pills, it was reported that the National Assembly is working on revising the Pharmaceutical Affairs Act so it can bar the advertising of the drug.
The marketing license for Mifegymiso
Korea Biomedical Review reported that Hyundai Pharm’s filing for approval for the abortion drug has gained attention because the Ministry of Health and Welfare already granted repayment for doctor’s education and counseling sessions about medical abortion.
The policy asks doctors to give educational counseling to pregnant women regarding abortion. They are allowed to explain the procedures for abortion, including precautions before and after the surgery. The physicians will also be taught about the physical and mental complications of abortion and contraception.
Meanwhile, Hyundai Pharm stated it will do its best to gain approval. “We will closely work with the drug developer to accelerate the regulatory nod for the drug,” a company official said.
